biologics
How LOTTE Biologics Plans to Become a Top-Ten Global Biomanufacturing CDMO
LOTTE Biologics did not exist four years ago. Today it is operating a 40,000-litre biomanufacturing campus in New York, running a dedicated antibody-drug conjugate facility, breaking ground on a $3.3 billion manufacturing campus in South Korea, and expanding its second antibody manufacturing agreement with a clinical-stage biotech targeting dual-paratopic cancer immunotherapy. The pace is intentional.…
Investors Eye Proteins Market: 9.5% Annual Growth Through 2030
Executive Summary The proteins and protein crystals market has become one of the most important pillars of modern biotechnology and biopharmaceuticals. Growth is being driven by rising demand for therapeutic proteins, advances in structural biology, and expanding use across healthcare, agriculture, food processing, and industrial applications. According to MarketsandMarkets, the market is expected to grow…
Sanofi’s Amlitelimab Clears Regulatory Bar, Raises New Investor Doubts
SNY performance by TradingView Sanofi (NASDAQ: SNY, Euronext Paris: SAN)’s amlitelimab still looks like a viable U.S. approval candidate, but it is no longer the clear successor to Dupixent that investors once hoped for. The latest data keeps the program alive from a regulatory standpoint, yet introduces enough uncertainty that the stock is unlikely to…
